Trial of Sequential Medications After TNF Failure (SMART) and Precision Treatment Decisions in Juvenile Idiopathic Arthritis

Project Period:

Grant Category:
Advancing Biosample Collection Grant

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Treating JIA continues to be a challenge. At least half of children with JIA have a more severe polyarticular form that is often refractory to treatment, leading to joint damage, impaired quality of life, disability, and increased healthcare costs. Powerful new biologic medications have improved outcomes, but a recent report from the CARRA Registry indicated that almost half of children with JIA still had active disease despite use of new biologics. The SMART (Trial of Sequential Medications AfteR TNF failure)-JIA trial aims to identify optimal treatment strategies and sequence of medications in children who fail an initial biologic. We aim to strengthen clinical decision-making by identifying biological markers that can predict failure to initial biologic treatment and response to next treatment. The overarching goal is to drive personalized, precision medicine for children with JIA.


Eveline Wu, MD, MS

The University of North Carolina at Chapel Hill

Anna Patrick, MD, PhD

Vanderbilt University Medical Center (VUMC)

Related Awarded Grants

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Genetic Ancestry Powered studies (GAPs) in JIA

Disease Area:
Juvenile Idiopathic Arthritis (JIA)

Pilot of Adalimumab Withdrawal